SUNNYVALE, Calif. and LANCASTER,
Pa., Feb. 24, 2015
/PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY) and
Lancaster General Health announced today that the first
commercially available InCise™ Multileaf Collimator (MLC) for the
CyberKnife® M6™ System has been received by Lancaster. The hospital selected the InCise
MLC based on its ability to increase the system's treatment
efficiency and extend its unique capabilities to a broader range of
patient cases.
Evaluation of the InCise MLC with the CyberKnife M6 system has
been successfully completed by two U.S. sites. Accuray conducted a
rigorous evaluation of the device covering a wide range of
functionality, performance, reliability and serviceability
parameters. The InCise MLC successfully met all predetermined
criteria to the company's and the sites' full satisfaction. Accuray
is now working closely with its supply chain network to scale up
manufacturing to meet commercial demand for the MLC.
The InCise MLC is the world's first multileaf collimator to be
available on a robotic platform, the CyberKnife M6 System. The
system was designed to deliver extremely precise stereotactic body
radiation therapy (SBRT). Using its unique robotic range of motion
and continuous image guidance, the system follows the target
throughout the treatment process, delivering individualized
treatment with sub-millimeter precision. The CyberKnife M6 System
can be used to treat tumors anywhere in the body, including the
prostate, lung, brain, spine, liver, pancreas and kidney, and may
offer hope to patients who have inoperable or surgically complex
tumors, or who may prefer a clinically effective, non-surgical
option.
"This is an important milestone for Accuray. It represents an
evolution in the CyberKnife System platform that we believe will
lead to meaningful improvements in the treatment of cancer for
clinicians and patients, and broaden the range of patients and
tumors that can be treated," said Joshua H.
Levine, president and chief executive officer of Accuray.
"For example, evaluations to date of the technical performance of
the device indicate that its use may result in a 30% to 40%
reduction in treatment times compared to current timeframes.
Patients will experience enhanced comfort from spending less time
on the treatment couch and clinicians will see efficiencies in
their ability to plan and deliver SBRT."
"We look forward to treating our first patient using the newly
configured CyberKnife M6 System. With the MLC we expect to reduce
SBRT treatment times without sacrificing the precision we've come
to expect from the system," said Jeffrey
Eshleman, MD, Director of Radiation Oncology, Lancaster
General Health. "In addition, the InCise MLC will expand patient
access to SBRT to those people who previously may not have been
eligible due to the size or type of their tumor. SBRT is typically
a much shorter course of treatment than conventional radiation
therapy. It has the potential to reduce the overall cost of patient
care, and discomfort and scheduling inconvenience for the patient,
versus conventional treatment."
About Accuray
Accuray Incorporated (Nasdaq: ARAY) is a radiation oncology company
that develops, manufactures and sells precise, innovative tumor
treatment solutions that set the standard of care with the aim of
helping patients live longer, better lives. The company's
leading-edge technologies deliver the full range of radiation
therapy and radiosurgery treatments.
Safe Harbor Statement
Statements made in this press release that are not statements of
historical fact are forward-looking statements and are subject to
the "safe harbor" provisions of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements in this press
release relate, but are not limited, to advantages of new
technology, clinical applications, clinical results, patient
outcomes, successful adoption of Accuray technologies, and
Accuray's leadership position in radiation oncology innovation and
technologies. Forward-looking statements are subject to risks and
uncertainties that could cause actual results to differ materially
from expectations, including but not limited to the risks detailed
under the heading "Risk Factors" in the company's report on Form
10-K, filed on August 29, 2014, the
company's reports on Form 10-Q, filed on November 7, 2014 and February 6, 2015, and the company's other filings
with the SEC.
Forward-looking statements speak only as of the date the
statements are made and are based on information available to the
company at the time those statements are made and/or management's
good faith belief as of that time with respect to future events.
The company assumes no obligation to update forward-looking
statements to reflect actual performance or results, changes in
assumptions or changes in other factors affecting forward-looking
information, except to the extent required by applicable securities
laws. Accordingly, investors should not put undue reliance on any
forward-looking statements.
About Lancaster General Health
Lancaster General Health is a three-hospital not-for-profit health
system located in South Central
Pennsylvania. Members of the LG Health system include the
533-bed Lancaster General Hospital (LGH), the 97-bed Women &
Babies Hospital, and the 59-bed Lancaster Rehabilitation Hospital.
Outpatient services are provided at 14 outpatient centers,
including Downtown and Suburban Outpatient Pavilions, three Urgent
Care sites and an LG Health Express location. Lancaster General
Health Physicians includes nearly 200 primary-care and specialist
physicians at nearly 40 practices throughout South Central PA.
Thrice designated a Magnet hospital for nursing excellence, LGH
has been recognized regionally and nationally for clinical
excellence and patient safety. Open-heart-surgery outcomes at its
Lancaster Heart & Vascular Institute are among the best in the
nation. Women & Babies offers comprehensive services including
deliveries, GYN services, surgical care and a 29-bed Neonatal
Intensive Care Unit offering South
Central PA's most advanced care for newborns with extreme
prematurity, acute low-birth weight and severe or complex
illnesses.
The system's Ann B. Barshinger Cancer Institute is the only
provider in Central PA to offer
multimodality radiosurgery, including Gamma Knife®,
TomoTherapy®, CyberKnife® M6™ and TrueBeam™
technology via an integrated-care approach. The system's
Pennsylvania College of Health
Sciences is a private, co-educational, Middle States-accredited
four-year college offering a variety of associate and baccalaureate
degree and certification programs in healthcare.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/lancaster-general-health-receives-first-commercial-incise-multileaf-collimator-for-the-cyberknife-m6-system-300040181.html
SOURCE Accuray Incorporated